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Arterial hypertension is a complex mul-
tifactorial disease and a global public
health concern. It is responsible for at
least 45% of deaths due to heart dis-
ease and 51% of deaths due to stroke,
adding up the tremendous number of
9.4 million deaths every year (Lim et al.,
2012; World Health Organization, 2013).
The renin-angiotensin-aldosterone system
(RAAS) is one of the most important reg-
ulatory systems of blood volume, arterial
pressure and cardiovascular homeostasis.
Angiotensin II (Ang II) is the principal
effector hormone of the RAAS in vas-
cular biology, mediating effects via two
main receptors: Angiotensin receptor type
1 (AT1) and type 2 (AT2) (Callera et al.,
2007). When Ang II binds to AT1 on
vascular smooth muscle cells, it mobi-
lizes intracellular Ca2+, leading to cellular
contraction. Sustained cellular contraction
increases peripheral vascular resistance,
resulting in high blood pressure (Touyz
and Schiffrin, 2000).
Among others, genetic factors are
closely related with the development
of hypertension. People with African
American and South Asian genetic
background have higher prevalence of
hypertension compared to Caucasians,
independently of their socioeconomic sta-
tus (Cappuccio, 1997; Sampson et al.,
2014). These differences in the ethnic
background can increase the prevalence
of hypertension by 2 fold until the age
of 55, when the differences decline, pre-
sumably because of the interfering effect
of age-related factors (Wolz et al., 2000).
Several polymorphisms have been asso-
ciated with higher prevalence of arterial
hypertension; there are 2 polymorphisms
in the Angiotensin Converting Enzyme
(ACE) and Angiotensin Converting
Enzyme 2 (ACE2) that lead to elevate
circulating Ang II levels (Giner et al., 2000;
Di Pasquale et al., 2004; Fan et al., 2007).
Interestingly, these same genetic variations
(the “D” allele of ACE I/D polymorphism
and the ACE2 C→T substitution) have
been associated with a lower incidence of
cerebral malaria (CM) in Indian adults,
although the later one only in women
(Dhangadamajhi et al., 2010).
Malaria is still a major public
health problem world wide, causing
approximately 600,000 deaths, mostly
among African children (World Health
Organization, 2012a). A high propor-
tion of these deaths are caused by CM, a
syndrome characterized by impaired con-
sciousness, generalized convulsions, coma
and neurological sequelae (Idro et al.,
2005). CM is caused by the interaction
between Plasmodium falciparum infected
erythrocytes and host brain endothelial
cells. Parasite proteins that are expressed
on the surface of infected erythrocytes
(PfEMP1), interact with host endothelial
cell receptors (Protein C receptor, ICAM-
1; Newbold et al., 1997; Turner et al., 2013)
leading to their sequestration within the
brain microcirculation. Disruption of the
blood-brain barrier is observed produc-
ing the characteristic petechiae and ring
hemorrhages found on the brain of dead
patients with CM (Rasti et al., 2004).
Although it is still not well-established
that Ang II has beneficial effects onmalaria
and particularly on CM, different lines
of evidence suggest a possible ‘protective’
effect that could be mediated by dif-
ferent, non-exclusive mechanisms that
could affect parasite development and/or
host susceptibility to Plasmodium-induced
pathology.
Recent reports have shown that
angiotensin peptides can induce impair-
ment of the erythrocytic cycle of
Plasmodium, reducing the parasite growth
in vitro (Maciel et al., 2008; Saraiva et al.,
2011). Since the development of CM
depends on the initial levels of para-
sitemia in mice (Amani et al., 1998) and
possibly in humans (Bejon et al., 2005),
this could be a potential explanation for
Ang II protection from CM. Our unpub-
lished results using mice infected with
Plasmodium berghei seem to confirm that
the elevation of Ang II levels results in
modestly decreased parasitemias in this
animal model.
It is possible that Ang II could mod-
ulate malaria severity through additional
mechanisms, specially, since the inhibitory
effect observed in parasite growth is mod-
est (Maciel et al., 2008; Saraiva et al.,
2011). Sodium conservation could pro-
vide an alternative explanation to the
protective effect of the polymorphisms
associated with higher levels of Ang II.
In this case, Ang II could be acting to
counterbalance hyponatremia by stimu-
lating the secretion of aldosterone from
the adrenal cortex, the major regulator of
Na+ reabsorption. Hyponatremia (serum
sodium < 135mmol/L) is frequent in
malaria patients and correlates with dis-
ease severity in imported malaria (van
Wolfswinkel et al., 2010). However, other
studies have shown that circulating Na+
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levels have no predictor value for the out-
come of malaria (Phillips et al., 2009) and
are not associated with increased mortality
(Hanson et al., 2009). Further investiga-
tions are necessary to elucidate the role
of serum Na+ levels in the outcome of
severe malaria and its possible relation
with polymorphisms of the RAAS.
A protective effect of Ang II against
CM may also be mediated by effects on
the host vascular endothelial cells. Ang II
exerts its vasoconstriction effect through
the AT1 receptor on vascular smooth mus-
cle cells (de Gasparo et al., 1990). However,
since the BBB is impermeable to Ang
II and other RAAS peptides, circulating
Ang II does not reach underlying vas-
cular muscular cells and vascular pres-
sure in the brain is locally regulated
by Ang II produced within the brain
parenchyma (Bader, 2010). In the con-
text of CM, higher levels of circulating
Ang II would not increase vasoconstriction
in the brain, but could affect endothelial
cells that form the BBB and express both,
AT1 and AT2 receptors. Using monolayers
of human brain microvascular endothe-
lial cells, we have observed that incu-
bation with erythrocytes infected with
Plasmodium falciparum promotes the dis-
ruption of interendothelial cell junctions
between these cells. Activation of AT2 or
inhibition of AT1 receptor preserves the
integrity of interendothelial cell junctions
after incubation with P. falciparum in vitro
and protect against experimental CM in
mice (Gallego-Delgado et al., 2013). This
could be key in the association of Ang II
with lower development of CM since AT2
receptor stimulation has protective effects
on brain injury (McCarthy et al., 2009;
Habashi et al., 2011) and inhibits vas-
cular endothelial cells migration (Falcon
et al., 2005). Gene expression analysis
comparing CM-susceptible mice vs. CM-
resistant mice also showed higher expres-
sion levels of the AT2 receptor gene in
CM-resistant mice compared to suscepti-
ble ones (Delahaye et al., 2007). Also, acti-
vation of AT2 receptor results in increased
production of nitric oxide by endothelial
Nitric Oxide Synthase (eNOS) in endothe-
lial cells (Yayama and Okamoto, 2008),
which could be protective against cerebral
malaria since low nitric oxide bioavailabil-
ity may exacerbate endothelial dysfunc-
tion and contributes to the pathogenesis
of severe malaria (Gramaglia et al., 2006;
Miller et al., 2013). Interestingly, poly-
morphisms in eNOS that are responsi-
ble for increased expression and nitric
oxide production have been associated
with mild malaria (Dhangadamajhi et al.,
2009, 2010).
Finally, it has also been proposed that
the effects of Ang II in malaria severity
could be mediated by immune mecha-
nisms, since activation of AT1 by Ang II is a
pro-inflammatory stimulus (Benigni et al.,
2010). In this case, elevated levels of Ang
II would result in higher inflammation
that would contribute to the activation
of endothelial cells and would be detri-
mental for the outcome of severe malaria.
Treatment of Plasmodium-infected mice
with losartan, an inhibitor of AT1, and
captopril, an inhibitor of ACE that reduces
the levels of Ang II, inhibit T cell activation
induced by infection (Silva-Filho et al.,
2013). Treatment with losartan, which
inhibits the signaling of Ang II through
AT1, while potentiating the effects medi-
ated by AT2, would result in decreased
endothelial cell migration and lower dis-
ruption of interendothelial cell junctions,
in addition to anti-inflammatory systemic
effects (Marchesi et al., 2008) and would
align with the hypothesis of a benefi-
cial effect of Ang II in malaria severity.
However, the effects of captopril, reducing
Ang II, decreasing parasitemia and pro-
tecting against experimental CM (Silva-
Filho et al., 2013), apparently do not agree
with the hypothesis that increased Ang II
provides protection against severe malaria.
Further experiments in vivo are necessary
to elucidate the signaling pathways, AT1
vs. AT2, mediating the observed effects
on malaria severity of different concen-
trations of systemic Ang II in parasite
development and generation of CM.
Humans have been infected by
P. falciparum for over 50,000 years (the
estimated date for the out-of-Africa
migration) and have co-evolved during
this time (Tanabe et al., 2010). Different
human polymorphisms, such as those
causing thalassemia or sickle cell ane-
mia, have been associated to this natural
selection process. Although there is not
sufficient evidence available to demon-
strate it, the association of polymorphisms
of the ACE and protection from severe
malaria may also be the result of a natural
selection process. This apparent contra-
diction would be explained if higher levels
of Ang II at early ages protect from CM.
In this case, those polymorphisms would
have a higher transmission ratio, despite
their deleterious effects during adult-
hood, as observed in people with African
American genetic background (Sampson
et al., 2014).
While hypertension has been tradition-
ally considered a disease of western coun-
tries, in the latest years it has become
obvious that hypertension is coming to
epidemic levels in Africa, even presenting
higher prevalence than in wealthier coun-
tries, possibly because of the higher lev-
els of circulating Ang II found in people
with African genetic background (Addo
et al., 2007; Lloyd-Sherlock et al., 2014).
As a consequence, a significant number of
African natives are currently taking anti-
hypertensive medication, and this number
is expected to increase exponentially in the
coming years (Lloyd-Sherlock et al., 2014).
If further investigations demonstrate that
Ang II levels influence the development
of CM, hypertension treatment in malaria
endemic areas should take this effect into
consideration.
Finding polymorphisms associated to
hypertension in Sub-Saharan Africa could
help to select the adequate antihyperten-
sive treatment in these highly vulnerable
populations (Mokwe et al., 2004; Peck
et al., 2013). The fact that differences
in the ethnic background correlate with
differences in the response to antihyper-
tensive drugs suggests that the genetic
background could be an essential factor
to consider when it comes to choose the
better antihypertensive regimen to control
blood pressure (Gupta, 2010; Gupta et al.,
2010).
Another population possibly affected
by the influence of anti-hypertensive med-
ication on malaria severity would be
travelers from western countries going
to malaria endemic areas. Nonimmune
malaria patients, such as travelers, are
more susceptible to succumb to CM
and develop neurological sequelae (Alrajhi
et al., 1999; Roze et al., 2001). But not all
nonimmune travelers have the same odds
to develop malaria complications. In a 16-
year period clinical study of natives from
malaria-nonendemic countries infected
withmalaria, Phillips et al. showed that the
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odds of severe malaria were 8-fold lower
among black than other ethnic groups
suggesting genetic factors to contribute
to the outcome of the disease (Phillips
et al., 2009). WHO estimates that over
100 countries with risk of malaria trans-
mission receive 125 million travelers every
year and reports 10,000 cases of malaria
among them (World Health Organization,
2012b). Given that∼20% of the adult pop-
ulation in western countries is hyperten-
sive, a significant number of those travelers
would be taking anti-hypertensive medi-
cation while in malaria endemic territo-
ries. A first line therapy for hypertension
treatment are the Angiotensin converting
enzyme inhibitors (ACEi) that inhibit the
production of Ang II from angiotensin I.
However, in malaria endemic areas, reduc-
ing the levels of systemic Ang II could
be reducing the chances of a good out-
come in the case of a malaria infection.
Alternative anti-hypertensive drugs, that
do not target ACE, for hypertensive trav-
elers would be decreasing the chances
of developing CM in case of acquiring
malaria.
Overall, there are evidences suggest-
ing that RAAS, and more specifically
Ang II, may influence the severity of
malaria. Although the available data are
still very limited, it is conceivable that
Ang II could be protecting the integrity of
the BBB in the setting of CM and giv-
ing a survival advantage to those that
carry polymorphisms resulting in higher
levels of systemic Ang II. Mechanistic
studies to determine the role of Ang II
in inflammation, endothelial cell bar-
rier formation, sodium conservation
and parasite growth in the context of
malaria are needed before any solid con-
clusions can be reached. It is possible
that polymorphisms acquired because
of their protective effect against malaria
have turned out to contribute together
with the western societies life-style to
the worldwide epidemic proportions
of hypertension. However, the avail-
able data in this sense are still scarce
and additional genetic studies are nec-
essary in other malaria endemic regions
(specially in sub-Saharan Africa) to
determine whether malaria could have
been a driving evolutionary force for
RAAS polymorphisms, and therefore for
hypertension.
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